الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenzavirusoverfladeantigener (hæmagglutinin og neuraminidase) af stamme a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vacciner - aktiv immunisering mod h5n1-subtype af influenza a-virus. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis europharm limited - travoprost, timolol - glaucoma, open-angle; ocular hypertension - oftalmologiske - reduktion af intraokulært tryk (iop) hos voksne patienter med åbenvinklet glaukom eller okulær hypertension, som ikke er tilstrækkeligt lydhør over for aktuelle beta-blokkere eller prostaglandinanaloger.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis europharm limited - indacaterol maleat - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - hirobriz breezhaler er indiceret til vedligeholdelsesbronkodilatorbehandling af luftstrømsobstruktion hos voksne patienter med kronisk obstruktiv lungesygdom.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol maleat - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - oslif breezhaler er indiceret til vedligeholdelsesbronkodilatorbehandling af luftstrømsobstruktion hos voksne patienter med kronisk obstruktiv lungesygdom.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol maleat - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - onbrez breezhaler er indiceret til vedligeholdelsesbronkodilatorbehandling af luftstrømsobstruktion hos voksne patienter med kronisk obstruktiv lungesygdom.